Literature DB >> 19950806

The continuous real-time 13C-octanoate breath test for patients with nonalcoholic steatohepatitis using the BreathID system.

Hironori Mawatari1, Masahiko Inamori, Koji Fujita, Masato Yoneda, Hiroshi Iida, Hiroki Endo, Kunihiro Hosono, Yuichi Nozaki, Kyoko Yoneda, Tomoyuki Akiyama, Hirokazu Takahashi, Ayumu Goto, Yasunobu Abe, Hiroyuki Kirikoshi, Noritoshi Kobayashi, Kensuke Kubota, Satoru Saito, Atsushi Nakajima.   

Abstract

BACKGROUND/AIMS: Hepatic mitochondrial beta-oxidation is considered to play a pivotal role in the pathogenesis of nonalcoholic steatohepatitis (NASH). The aim of this study was to determine whether there were differences between patients with NASH and healthy controls in a breath test with 13C-octanoate, a medium-chain fatty acid.
METHODOLOGY: The subjects were 8 patients (5 men, 3 women, median age 46.5 years) with histologically proven NASH and 6 healthy controls (5 men, 1 women, and median age 27.8 years). The 13C breath test was performed for 4 hours using the BreathID system with a 100 mL of water containing 100 mg 13C-octanoate.
RESULTS: There were no significant differences between NASH patients and controls about all breath test parameters.
CONCLUSIONS: NASH-mediated changes in breath test parameters after ingestion of 13C-octanoate were not observed in our study. The present study findings suggest the possible preservation of 13C-octanoate metabolism (mitochondrial beta-oxidation) in patients with NASH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19950806

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  4 in total

1.  Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction.

Authors:  Jeffrey D Browning; Jonathan A Baker; Thomas Rogers; Jeannie Davis; Santhosh Satapati; Shawn C Burgess
Journal:  Am J Clin Nutr       Date:  2011-03-02       Impact factor: 7.045

2.  Change of gastric emptying with chewing gum: evaluation using a continuous real-time C breath test (BreathID system).

Authors:  Yasunari Sakamoto; Shingo Kato; Yusuke Sekino; Eiji Sakai; Takashi Uchiyama; Hiroshi Iida; Kunihiro Hosono; Hiroki Endo; Koji Fujita; Tomoko Koide; Hirokazu Takahashi; Masato Yoneda; Chikako Tokoro; Ayumu Goto; Yasunobu Abe; Noritoshi Kobayashi; Kensuke Kubota; Shin Maeda; Atsushi Nakajima; Masahiko Inamori
Journal:  J Neurogastroenterol Motil       Date:  2011-04-27       Impact factor: 4.924

Review 3.  European guideline on indications, performance and clinical impact of 13 C-breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC.

Authors:  Jutta Keller; Heinz F Hammer; Paul R Afolabi; Marc Benninga; Osvaldo Borrelli; Enrique Dominguez-Munoz; Dan Dumitrascu; Oliver Goetze; Stephan L Haas; Bruno Hauser; Daniel Pohl; Silvia Salvatore; Marc Sonyi; Nikhil Thapar; Kristin Verbeke; Mark R Fox
Journal:  United European Gastroenterol J       Date:  2021-06-14       Impact factor: 4.623

4.  1-13C-propionate breath testing as a surrogate endpoint to assess efficacy of liver-directed therapies in methylmalonic acidemia (MMA).

Authors:  Irini Manoli; Alexandra R Pass; Elizabeth A Harrington; Jennifer L Sloan; Jack Gagné; Samantha McCoy; Sarah L Bell; Jacob D Hattenbach; Brooks P Leitner; Courtney J Duckworth; Laura A Fletcher; Thomas M Cassimatis; Carolina I Galarreta; Audrey Thurm; Joseph Snow; Carol Van Ryzin; Susan Ferry; Nicholas Ah Mew; Oleg A Shchelochkov; Kong Y Chen; Charles P Venditti
Journal:  Genet Med       Date:  2021-04-05       Impact factor: 8.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.